KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza) pre-treated patients with metastatic castration-resistant prostate cancer (mCRPC)

Gravis G.,Kolinsky M.,Mourey L.,Piulats J.M.,Sridhar S.,Romano E.,Berry W.,Gurney H.,Retz M.,Appleman L.,Boegemann M., De Bono J.,Joshua A.,Emmenegger U.,Conter H.,Laguerre B.,Wu H.,Schloss C.,Poehlein C.,Yu E.Y.

JOURNAL OF CLINICAL ONCOLOGY（2020）

Cited 10|Views3

No score

Abstract

103Background: KEYNOTE-365 (NCT02861573) is a phase 1b/2 study to evaluate pembro in combination with other agents in mCRPC. Here we report updated results from cohort B (pembro + docetaxel and pre...

Translated text

Key words

Enzalutamide,Docetaxel,Pembrolizumab,Prednisone,Cohort,Oncology,Medicine,Abiraterone,Castrate-resistant prostate cancer,Internal medicine

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined